OrbiMed

OrbiMed (OrbiMed Advisors LLC) is a leading global healthcare-dedicated investment firm founded in 1989 and headquartered in New York City. The firm manages approximately $20 billion in AUM across public equity, private equity, and private credit/royalty strategies, with a portfolio of 500+ companies and over 130 venture-backed IPOs. It invests across the full healthcare spectrum — from seed-stage startups to large publicly traded multinationals — covering biopharmaceuticals, medical devices, diagnostics, drug discovery tools, and healthcare IT and services. OrbiMed typically acts as a lead investor in private equity deals and also provides non-dilutive structured debt and royalty monetization financing to commercial-stage companies. The firm's most recent private fund raise (October 2023) totaled over $4.3 billion across OrbiMed Private Investments IX, OrbiMed Asia Partners V, and OrbiMed Royalty & Credit Opportunities IV; in August 2025 it closed OrbiMed Royalty and Credit Opportunities Fund V at $1.86 billion. The team of 150+ professionals operates from a dozen global offices including New York, London, San Francisco, Shanghai, Hong Kong, Mumbai, and Herzliya.